Poolbeg Pharma's Capital-Light Model For New Anti-Infectives Development
UK Spin Out Completes IPO And Will List On AIM
Executive Summary
A new UK company, Poolbeg Pharma, has been set up to develop new anti-infectives in an efficient manner, and already has a repositioned MAP kinase inhibitor for the treatment of severe influenza ready for Phase II studies.
You may also be interested in...
Clinical Insights Drive BiVictriX's Approach To Targeted Cancer Therapies
The UK biotech BiVictriX has completed a fundraising and listing on the UK’s AIM to support the development of antibody drug conjugates with “twin-antigen” targeting that could improve the selectivity of cancer therapeutics, with its lead candidate going up against acute myeloid leukemia.
IPO Update: Booming Biopharma On Pace For Another Record Year
Only 25 more initial public offerings are needed for 2021 to beat 2020’s record-breaking 86 IPOs. However, the average return for this year’s offerings is just 1.1% as of 1 July versus 11% at the end of the first quarter.
Amryt Predicts $1bn Revenues After Chiasma Acquisition
The Irish drugmaker will have three approved commercial products for rare diseases – Mycapssa, Lojuxta and Myalept – with a potential fourth therapy on the way now Filsuvez has been filed for butterfly skin.